Share of cheap drugs rapidly declining in Russia

7 February 2024
price_transparency_money_large

The share of cheap drugs in the Russian pharmaceutical market is steadily declining, while in the last three years their overall range in the market has declined two-fold, reports The Pharma Letter’s local correspondent.

According to Russian pharma analytics agency DSM Group, in 2023, the overall range of drugs in Russian pharmacies fell by 11% compared to the previous year - from 21.600 to 19.400 trade items, and the decline is ongoing.

The largest drop over the year was observed in case of the cheapest drugs with the cost of $1.50-$2.00. Their number decreased by 24% year-on-year - from 5.700 trading positions in 2022 to 4.600 units.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics